Precigen (PGEN) closed at $4.54 on November 13, 2026, down 2.6% from the previous close, on volume of 3,457,632 shares (30-day average 6,605,631).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Calendar Call Spread | 16-Oct-26 : 15-Jan-27 5.5 C | 360 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Precigen Earnings Call Highlights PAPZIMEOS Growth
TipRanks (Sat, 14-Nov 10:38 PM ET)
ACCESS Newswire (Tue, 10-Nov 6:30 AM ET)
PRNewswire (Wed, 4-Nov 4:05 PM ET)
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
PRNewswire (Wed, 28-Oct 4:06 PM ET)
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
PRNewswire (Mon, 21-Sep 7:00 AM ET)
ACCESS Newswire (Tue, 25-Aug 7:00 AM ET)
PGEN Achieves Profitability on Accelerating PAPZIMEOS Revenue and Expands US Market Reach
Market Chameleon (Wed, 5-Aug 3:36 AM ET)
Market Chameleon (Fri, 12-Jun 6:33 AM ET)
Market Chameleon (Thu, 14-May 6:16 AM ET)
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Precigen trades on the NASDAQ stock market under the symbol PGEN.
As of November 16, 2026, PGEN stock price declined to $4.30 with 2,741,429 million shares trading.
PGEN has a beta of 1.48, meaning it tends to be more sensitive to market movements. PGEN has a correlation of 0.04 to the broad based SPY ETF.
PGEN has a market cap of $1.54 billion. This is considered a Small Cap stock.
Last quarter Precigen reported $74 million in Revenue and $.08 earnings per share. This beat revenue expectation by $2 million and met earnings estimates .
In the last 3 years, PGEN traded as high as $8.98 and as low as $.65.
The top ETF exchange traded funds that PGEN belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.
PGEN has outperformed the market in the last year with a return of +11.4%, while the SPY ETF gained +11.1%. However, in the most recent history, PGEN shares have underperformed the stock market with its stock returning -33.7% in the last 3 month period and -38.0% for the last 2 week period, while SPY has returned -4.7% and -2.2%, respectively.
PGEN support price is $4.31 and resistance is $4.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PGEN shares will trade within this expected range on the day.